Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12934808 | 0.90 | FAP (0.39) | ITGB3ITGA2BPREP | |
| SCHEMBL2082334 | 0.89 | FOLH1 (0.49) | FOLH1ITGB3ITGA2B | |
| SCHEMBL8256331 | 0.87 | ITGB3 (0.42) | FOLH1ITGB3ITGA2BPREP | |
| SCHEMBL28769352 | 0.84 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BMMEECE1 | |
| SCHEMBL22964984 | 0.84 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BMMEECE1 | |
| SCHEMBL24555462 | 0.84 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BMMEECE1 | |
| SCHEMBL1815135 | 0.84 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BMMEECE1 | |
| SCHEMBL2084143 | 0.83 | PREP (0.47) | PREP | |
| SCHEMBL12934807 | 0.82 | PREP (0.39) | ITGB3ITGA2BPREP | |
| SCHEMBL2084495 | 0.81 | PREP (0.45) | PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863304-B2 | Analogs of glycyl-prolyl-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-01-04 | — | — | US | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | FOLH1 172/4885ITGB3 4373/4885ITGA2B 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.